Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination CagriSema vs Tirzepatide: Weight Loss Results in REDEFINE 4 Trial Paramesh Shamanna posted on the topic LinkedIn Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Cagrilintide: Benefits, Dosage, and Weight Loss Potential Explained obesitymedicine #medicalnews #clinicaltrials #cagrisema #zepbound # tirzepatide #semaglutide #weightloss #healthcare Joseph Zucchi, PA C, MPAS 10 comments